High Dose Interleukin-2 (IL-2) Therapy In 'Lymphodepleted Primed' Patients With Metastatic Melanoma.

Trial Profile

High Dose Interleukin-2 (IL-2) Therapy In 'Lymphodepleted Primed' Patients With Metastatic Melanoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Apr 2013

At a glance

  • Drugs Aldesleukin (Primary) ; Cyclophosphamide (Primary) ; Fludarabine (Primary) ; Sargramostim (Primary) ; Mesna
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Oct 2011 Actual end date (March 2010) added as reported by ClinicalTrials.gov.
    • 25 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 15 Feb 2008 Status change from recruiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top